CervoMed Completes Enrollment In Phase 2b RewinD-LB Clinical Trial Of Neflamapimod For The Treatment Of Patients With Dementia With Lewy Bodies
Portfolio Pulse from Benzinga Newsdesk
CervoMed Inc. (NASDAQ:CRVO) has completed enrollment in its Phase 2b RewinD-LB clinical trial for neflamapimod, aimed at treating dementia with Lewy bodies. Topline data is expected in December 2024, and the trial design is optimized for success, potentially paving a clear path to market.
June 11, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CervoMed Inc. has completed enrollment in its Phase 2b trial for neflamapimod, targeting dementia with Lewy bodies. With topline data expected in December 2024, the trial's success could significantly impact the company's market position.
The completion of enrollment in a Phase 2b trial is a significant milestone for CervoMed. The trial's design is optimized for success, and positive results could lead to a clear path to market, potentially boosting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100